After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...